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Background: Patients with nocturnal hypertension are at higher risk for cardiovascular 
complications such as myocardial infarction and cerebrovascular insult. Published studies 
inconsistently reported decreases in nocturnal blood pressure with melatonin.
Methods: A meta-analysis of the efficacy and safety of exogenous melatonin in ameliorating 
nocturnal blood pressure was performed using a random effects model of all studies   fitting 
the inclusion criteria, with subgroup analysis of fast-release versus controlled-release 
preparations.
Results: Seven trials (three of controlled-release and four of fast-release melatonin) with 221 
participants were included. Meta-analysis of all seven studies did not reveal significant effects 
of melatonin versus placebo on nocturnal blood pressure. However, subgroup analysis revealed 
that controlled-release melatonin significantly reduced nocturnal blood pressure whereas fast-
release melatonin had no effect. Systolic blood pressure decreased significantly with controlled-
release melatonin (−6.1 mmHg; 95% confidence interval [CI] −10.7 to −1.5; P = 0.009) but not 
fast-release melatonin (−0.3 mmHg; 95% CI −5.9 to 5.30; P = 0.92). Diastolic blood pressure 
also decreased significantly with controlled-release melatonin (−3.5 mmHg; 95% CI −6.1 to 
−0.9; P = 0.009) but not fast-release melatonin (−0.2 mmHg; 95% CI −3.8 to 3.3; P = 0.89). 
No safety concerns were raised.
Conclusion: Add-on controlled-release melatonin to antihypertensive therapy is effective and 
safe in ameliorating nocturnal hypertension, whereas fast-release melatonin is ineffective. It is 
necessary that larger trials of longer duration be conducted in order to determine the long-term 
beneficial effects of controlled-release melatonin in patients with nocturnal hypertension.
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Introduction
The diurnal pattern of blood pressure is an important factor in determining 
cardiovascular complications in hypertensive patients. Impaired nocturnal blood 
  pressure fall is associated with a high risk of developing target organ damage1 and 
morbid cardiovascular events.2 The mechanism responsible for the reduction in blood 
pressure during sleep and the pathophysiological explanations for the lack of this 
nocturnal fall remain unclear.
Melatonin is a hormone normally secreted from the pineal gland at night. It serves 
as the signal of darkness in the organism, and as such plays a pivotal role in the 
physiological regulation of circadian rhythms, including sleep.3 Evidence from the last 
ten years suggests that melatonin may influence the cardiovascular system in humans.4 
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Furthermore, exogenous melatonin has induced several 
hemodynamic effects in healthy men and women.5–7
Several studies have evaluated the effects of melatonin on 
nocturnal blood pressure.8–14 The results were not   consistent, 
as in some studies melatonin reduced, and in some it did 
not, or even increased nocturnal blood pressure. Not all 
studies used the same melatonin formulation, ie, some used 
controlled-release formulations and others used fast-release 
formulations. We hypothesized that the inconsistent results 
in the various studies may be related to the formulation used. 
Therefore, we conducted a meta-analysis to assess the effect 
of melatonin on nocturnal blood pressure and further ana-
lyzed the data by type of melatonin formulation used.
Methods
Data sources
We searched the PubMed database for randomized, placebo-
controlled studies which were published between January 
1980 and December 2010, using melatonin in humans and 
in which the primary endpoint reported was blood pressure. 
For this search, we used the terms melatonin, blood pressure, 
and clinical trials. Pertinent articles cited as references in the 
identified trials and reviews were also culled. We included only 
studies that compared the effect of melatonin with placebo, 
reported nocturnal systolic and diastolic blood pressure as 
measured by 24-hour ambulatory blood pressure monitoring 
for blood pressure assessment, and were published in the 
English language. We excluded open-label studies and studies 
that were not randomized, controlled, or used melatonin 
agonists. Two reviewers assessed the methodological quality 
of these seven studies independently using the Jadad scale.15 
Papers with a Jadad scale result of three or more were judged 
as suitable for this meta-analysis.
Data extraction
We extracted from each paper the patient characteristics, the 
melatonin formulation and dose, duration of treatment, base-
line blood pressure, and nocturnal blood pressure values after 
treatment. We also extracted from the studies the number of 
patients in the melatonin and in the placebo groups. For the 
crossover studies, we counted the patients twice, once in the 
active group and once in the placebo group. The meta-analysis 
was calculated with reported endpoints for melatonin and pla-
cebo treatments for both the crossover and parallel studies.
Data analysis
Because all of the studies compared melatonin with pla-
cebo, we considered our study as a direct head-to-head 
comparison of two treatments (placebo versus melatonin). The 
meta-analysis was performed using the software program MIX 
2 (Meta-analysis with Interactive eXplanations, version 2). 
The descriptive method was used, and the input was the results 
of the blood pressure parameters as described previously. All 
of these measures could therefore be defined as continuous 
(noted by mmHg), by utilizing the random effects method. 
The alpha level was set at 0.05 for each outcome.
We assessed per parameter the overall mean difference, 
the 95% confidence interval (CI) and the z score. The cross-
over and parallel studies were done simultaneously. The 
results were also assessed according to the melatonin formu-
lation, irrespective of age. We have presented the results in 
standard forest plots containing mean differences, 95% CI, 
weight of each study, and pooled analysis.
Results
study characteristics
Altogether 63 articles on melatonin and blood pressure were 
found. Twenty-five trials did not use exogenous melatonin and 
20 trials using exogenous melatonin did not test nocturnal 
blood pressure and were therefore excluded. The full texts of 
all articles thought to be potentially relevant were retrieved 
(n = 12) and read by two reviewers (EG and ML). After care-
ful evaluation, only seven studies met the inclusion criteria 
and qualified to be included in the meta-analysis (Figure 1). 
The mean quality score was 3.8 out of 5 (range 3–5) based 
on the Jadad scale. Of the seven placebo-controlled studies, 
six studies involved 200 adults and one study involved 21 
adolescents. Of the subjects included in the analysis, 60 had 
coronary artery disease, 11 had type 1 diabetes, 51 were 
normotensive, and 99 had hypertension (Table 1). One study 
reported the results separately for the normotensive and 
diabetic patients, and therefore was included as two separate 
studies in the meta-analysis.8
In three studies, patients received either melatonin or 
placebo in parallel, and in the other three adult studies and 
the adolescent study treatments were given in a crossover 
design. In the three parallel-group studies, the treatment 
duration ranged from 28 to 90 days. In two of the three 
crossover studies in adults, the participants received the trial 
medication during two consecutive periods of three weeks 
each that were not separated by a washout period. In the 
other adult crossover study, the trial medications were given 
for two subsequent periods of four weeks each, separated 
by a four-week washout period. In the adolescent crossover 
trial, the participants received the trial medications for two 
consecutive periods of one week, separated by a one-week Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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63 records identified through
database searching
1 additional record identified
in the references of the records
63 records after 1 duplicate removed
63 records screened
51 records excluded
25 no RCT
20 no nocturnal BP data
2   not english
2   reviews
2   melatonin agonists
5 full-text articles
excluded
4 no RCT
1 no ABPM
12 full-text articles
assessed for eligibility
7 studies included in
qualitative synthesis
7 studies included in
quantitative synthesis
(meta-analysis)
Figure 1 Flowchart of the study selection process.
washout period. Altogether the analysis included 344 data 
points recorded from 221 subjects.
Dosage and formulations
In four studies that included 149 subjects, fast-release mela-
tonin at a dosage of 5 mg was used, and in three studies that 
included 72 subjects, controlled-release melatonin at a dos-
age of 2–3 mg was used. In this meta-analysis, the dosage 
was not taken into account.
systolic blood pressure
Meta-analysis based on all seven studies showed that mela-
tonin treatment decreased nocturnal systolic blood pressure 
slightly and insignificantly compared with placebo. The 
net effect of melatonin over placebo on nocturnal systolic 
blood pressure was −2.3 mmHg (95% CI −6.94 to 2.45; 
P = 0.35, Table 2). Analysis of the data according to the 
formulation shows that controlled-release melatonin signifi-
cantly reduced while fast-release melatonin had no effect 
on nocturnal systolic blood pressure (Figure 2, Table 2). 
Thus, systolic blood pressure decreased by 6.1 mmHg (95% 
CI −10.69 to −1.50; P = 0.009) with controlled-release 
melatonin whereas it decreased by only 0.27 mmHg (95% 
CI −5.88 to 5.33; P = 0.92) with fast-release melatonin 
(Figure 2, Table 2).
Diastolic blood pressure
Meta-analysis based on all seven studies showed that 
melatonin treatment decreased nocturnal diastolic blood 
pressure slightly and nonsignificantly. The net effect of 
melatonin over placebo on nocturnal diastolic blood pres-
sure was −1.4 mmHg (95% CI −4.01 to 1.29; P = 0.31, 
Table 3).   Analysis of the data according to the formulation 
used showed that controlled-release melatonin significantly 
reduced while fast-release melatonin had no effect on noc-
turnal diastolic blood pressure; diastolic blood pressure 
decreased by 3.51 mmHg (95% CI −6.14 to −0.86; P = 0.009) 
with controlled-release melatonin, whereas it decreased by Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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only 0.24 mmHg (95% CI −3.76 to 3.28; P = 0.89) with 
fast-release melatonin (Figure 2, Table 3).
safety
No serious adverse events were reported in the seven   studies 
included in the meta-analysis. Adverse events, including head-
ache, drowsiness, weakness, and nightmares, were reported 
in three studies.8,10,12 No significant side effects were noted in 
the other four studies. Based on available studies and clini-
cal use, melatonin is generally regarded as safe.16 Available 
trials report that overall adverse effects are not significantly 
more common with melatonin than placebo. The safety 
of melatonin in hypertensive patients is good, and implies 
that add-on melatonin therapy does not present   significant 
risks of detrimental drug interactions with the main major 
drugs used to treat hypertension. It is necessary that trials 
of longer duration be conducted in order to   determine the 
long-term safety of melatonin in patients with nocturnal 
hypertension.
Discussion
The results of this meta-analysis when including all 
  double-blind, placebo-controlled ambulatory blood pressure 
monitoring trials do not provide evidence that exogenous 
melatonin significantly reduces nocturnal blood   pressure. 
However, the originally planned subgroup analyses intended 
to evaluate the impact of the melatonin formulation used (fast-
release or controlled-release) on the outcome revealed that 
administration of controlled-release melatonin preparations 
consistently and significantly reduced nocturnal blood 
Table 2 effect of FR and cR-melatonin on systolic nocturnal blood pressure
Study N md ci- ci+ z P w
FR melatonin Lusardi12  42 −4.10 −9.48 1.284 −1.493 0.136 14.34%
Lusardi10 94 6.70 3.66 9.739 4.321 0.000 16.45%
cavallo8 (Diabetics) 22 −1.40 −9.80 7.004 −0.326 0.744 11.28%
cavallo8 (controls) 20 −0.80 −8.69 7.093 −0.199 0.843 11.78%
Rechcinski13 60 −4.10 −12.49 4.290 −0.958 0.338 11.30%
Total FR melatonin 238 −0.27 −5.879 5.337 −0.095 0.925
cR melatonin scheer9 32 −5.60 −14.07 2.870 −1.296 0.195 11.22%
cagnacci14 36 −3.70 −12.43 5.032 −0.830 0.406 10.97%
Grossman11 38 −8.00 −15.02 −0.976 −2.232 0.026 12.66%
Total cR melatonin 106 −6.10 −10.698 −1.505 −2.602 0.009
All studies Total 344 −2.25 −6.94 2.45 −0.938 0.348
Notes: The following parameters are reported: Number of data points (N); Mean BP difference between melatonin and placebo treatments (md); Lower-bound confidence 
interval (ci−); Upper-bound confidence interval (ci+); Z-value (Z); P-value (P); Weight (W) given to each study is calculated by the inverse sum of the within study and 
between study variance estimates.
Abbreviations: FR, fast release; cR, controlled release.
Table 1 Details of the studies included in the meta-analysis
Study No. subjects/
disease
Gender 
(M/F)
Age  
(years)  
(mean ± SD)
Melatonin 
treatment 
dose/
formulation
Duration 
(days)
Initial BP  
(mmHg)
The effect of melatonin   
on nocturnal systolic/ 
diastolic BP (mmHg),  
change from baseline
Parallel group studies
Lusardi et al12 21 Norm. 7/14 25 ± 2 5 mg /FR 28 NA −4/−1
Lusardi et al10 50 eHT 28/22 54 ± 4 5 mg/FR 28 136/72 −7*/−3*
Grossman et al11 38 eHT 22/16 63 ± 11 2 mg/cR 28 Plc: 137/72 
Mel. 136/72
−6*/−3*
Crossover studies
cavallo et al8 21 Norm (10)  
Diabet. (11)
14/7 16 ± 2 5 mg/FR 7 NA −1/−1 (Diabet) 
−0.5/−2 (Norm)
cagnacci et al14 18 eHT + Norm. 0/18 53 ± 1 3 mg/cR 21 NA −4*/−4*
scheer et al9 16 eHT 16/0 55 ± 8 2.5 mg/cR 21 NA −6*/−4*
Rechchinski et al13 60 cAD 44/16 57 ± 7 5 mg/FR 90 Plc: 118/66 
Mel. 117/65
−4*/−2
Note: *P , 0.05 vs baseline.
Abbreviations: Norm, normotensive; eHT, essential hypertension; Diabet, Diabetes type i; cAD, coronary artery disease; Plc, placebo; Mel, melatonin; FR, fast release; cR, 
controlled release; NA, not applicable; BP, blood pressure.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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pressure as compared with placebo treatment. The decrease 
in nocturnal blood pressure with controlled-release melatonin 
versus baseline was also evident in each and every study 
separately. The use of melatonin was safe with respect to 
adverse events experienced, as was observed in other studies 
that used melatonin.16
The mean reduction in nocturnal blood pressure was of a 
magnitude that is considered to be clinically relevant. Thus, 
with controlled-release melatonin, systolic blood pressure was 
reduced by 6 mmHg and diastolic blood pressure by 3 mmHg. 
The various studies were remarkably consistent in the nature 
and extent of the effects of bedtime controlled-release mela-
tonin on blood pressure, and most of the benefit was observed 
in the late night-early morning hours, when blood pressure 
elevation is on the rise. Importantly, the fast-release melatonin 
doses (5 mg) exceeded those of the controlled-release prepara-
tions (2–3 mg), and their inability to decrease nocturnal blood 
pressure is therefore not related to a lower dose.
Endogenous melatonin secretion starts soon after the 
onset of darkness, peaks in the middle of the night, and gradu-
ally declines thereafter towards the morning.3 Diminished 
melatonin production at night with normal day production 
is consistently reported in severely hypertensive patients 
and in hypertensive patients with nondipping blood pressure 
patterns.17–19 Melatonin deficiency has also been found in 
patients with coronary heart disease.20,21
Melatonin is rapidly metabolized, with an elimination 
half-life of 40–50 minutes.22,23 Following oral administration 
of exogenous fast-release melatonin, peak plasma levels are 
reached 20–30 minutes after ingestion, which are then main-
tained for 90 minutes and rapidly decline afterwards.24 Fast-
release melatonin formulations are thus unable to provide 
melatonin for the second half of the night. Controlled-release 
formulations circumvent the fast clearance of the hormone 
and provide melatonin profiles in the blood that more closely 
match the normal physiological release. Therefore, in order 
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Figure 2 effect of FR and cR-melatonin on nocturnal systolic/diastolic BP. effect of FR and cR-melatonin on systolic blood pressure (left panel) and diastolic blood pressure 
(right panel). The following parameters are reported: Mean difference (md); Confidence interval (Ci).Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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for exogenous melatonin to be present during the late part of 
the night, it has to be administered via a controlled-release 
preparation, or at very high doses.
Melatonin may lower blood pressure via several 
mechanisms. Vascular melatoninergic receptors have been 
demonstrated and shown to be functionally linked with 
vasoconstrictor or vasodilatory effects of melatonin.5 Other 
neurohormonal properties of melatonin, such as sympathetic 
inhibition, could also contribute to its cardioprotective 
effects.25 Impaired nocturnal sympathetic suppression with 
sustained adrenergic activity during sleep was reported 
in patients with nocturnal hypertension (nondippers).26,27 
Administration of melatonin may therefore contribute to 
the nocturnal suppression of the sympathetic nervous sys-
tem. The reduction of the activity of the oxidative enzyme, 
myeloperoxidase, by melatonin may also contribute to 
the vasoprotective and blood pressure-lowering effects of 
melatonin.28 Melatonin may also dilate peripheral arteries 
directly,5–7 thereby reducing peripheral resistance and leading 
to a nocturnal blood pressure fall. Moreover, melatonin has 
been shown to stimulate the release of tissue factor pathway 
inhibitor from the vascular endothelium, which may suppress 
thrombosis and arterial restenosis.29
A blunted nocturnal decrease in blood pressure is 
independently associated with increased aortic stiffness 
in patients with nocturnal hypertension. Carotid-femoral 
pulse wave velocity, a direct measure of aortic stiffness, 
has become increasingly important for total cardiovascular 
risk estimation.30,31 Even in dippers, absolute night-time 
blood pressure is associated more closely with pulse wave 
velocity than is daytime blood pressure.32 In a recent study, 
increased levels of melatonin during the night were found to 
cause a decrease in velocity of the aortic pulse wave, along 
with blood pressure.33 Moreover, melatonin administra-
tion, compared with placebo, has been found to decrease 
pulse wave velocity and systolic blood pressure in the 
supine position in healthy young men.34 Administration of 
controlled-release melatonin may thus replenish the cycle of 
an important cue of blood pressure control in patients with 
nocturnal hypertension.
A controlled-release melatonin formulation (Circadin®) 
has recently been approved in the European Union and other 
countries for the treatment of insomnia in patients aged 
55 years and older. However, it should be noted that the 
improvement in nocturnal hypertension appears to be related 
to the mechanism of action of controlled-release melatonin 
and not to the hypnotic action per se. Thus, benzodiazepine 
and benzodiazepine-like hypnotics that treat insomnia 
effectively do not improve hypertension. In fact, zolpidem, 
which is the most widely prescribed hypnotic drug, does not 
lower and may even increase nocturnal blood pressure.35,36 
Furthermore, the effect of zolpidem on blood pressure is seen 
in the early morning hours, at the time when blood pressure 
elevation has been implicated as a risk for cardiovascular 
events.37
The clinical relevance of a decrease of 6 mmHg 
in systolic and 3 mmHg in diastolic blood pressure in 
reducing the risk of cardiovascular complications in patients 
with hypertension can be evaluated in view of recent 
studies looking at the Spanish Society of Hypertension 
Ambulatory Blood Pressure Monitoring Registry.38,39 The 
prevalence of nondipping/nocturnal hypertension among 
untreated hypertensive patients in Spain was found to 
be 41%. In patients treated with antihypertensive drugs, 
53% had nondipping/nocturnal hypertension despite 
pharmacotherapy,38 indicating that antihypertensive 
Table 3 effects of FR and cR-melatonin on diastolic nocturnal blood pressure
Study N md ci- ci+ z P w
FR melatonin Lusardi12 42 −1.10 −6.44 4.240 −0.404 0.686 11.26%
Lusardi10 94 4.60 1.77 7.430 3.186 0.001 16.77%
cavallo8 (Diabetics) 22 −1.20 −8.45 6.048 −0.325 0.746 8.13%
cavallo8 (controls) 20 −2.10 −5.41 1.211 −1.243 0.214 15.67%
Rechcinski13 60 −3.10 −8.46 2.256 −1.134 0.257 11.23%
Total FR melatonin 238 −0.24 −3.766 3.281 −0.135 0.893
cR melatonin scheer9 32 −3.90 −7.68 −0.118 −2.021 0.043 14.58%
cagnacci14 36 −3.70 −8.21 0.810 −1.608 0.108 12.96%
Grossman11 38 −2.00 −8.39 4.391 −0.613 0.540   9.40%
Total cR melatonin 106 −3.51 −6.147 −0.868 −2.605 0.009
All studies Total 344 −1.36 −4.01 1.29 −1.008 0.313
Notes: The following parameters are reported: Number of data points (N); Mean BP difference between melatonin and placebo treatments (md); Lower-bound confidence 
interval (ci−); Upper-bound confidence interval (ci+); Z-value (Z); P-value (P); Weight (W) given to each study is calculated by the inverse sum of the within study and between 
study variance estimates.
Abbreviations: FR, fast release; cR, controlled release.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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treatment, while having a general blood pressure-lowering 
effect, does not restore proper circadian rhythms in blood 
pressure. The cardiovascular risk adjustment per 5 mmHg 
reduction in nocturnal systolic blood pressure of patients 
aged 55 years and above (adjusted by age and gender) has 
been shown to be 0.92 (95% CI 0.88–0.96) and per 5 mmHg 
reduction in nocturnal diastolic blood pressure it is 0.82 
(95% CI 0.77–0.88).39 A decrease of 5 mmHg in mean asleep 
systolic blood pressure or 2.1 mmHg in diastolic blood 
pressure saved 1585 events per 100,000 patient years.39
The results of this study suggest that addition of con-
trolled-release melatonin at night to stable antihypertensive 
treatment may improve nocturnal blood pressure control. 
Thus, because of its effects on nocturnal blood pressure, 
add-on controlled-release melatonin treatment is expected 
to reduce the cardiovascular risk in high-risk patients with 
nocturnal hypertension.40 Because the reviewed studies were 
relatively small size and short-term, additional large studies 
employing long-term administration of controlled-release 
melatonin are needed to substantiate the benefits of this 
add-on treatment in reducing risk of complications in patients 
with hypertension.
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